Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK plus non-small cell lung cancer (NSCLC): ALTA-1L final results
Authors
Tiseo, M.Popat, S.
Kim, H. R.
Ahn, M. J.
Yang, J. C.
Han, J. Y.
Hochmair, M. J.
Lee, K. H.
Delmonte, A.
Campelo, M. R. G.
Kim, D. W.
Griesinger, F.
Felip, E.
Califano, Raffaele
Spira, A. I.
Gettinger, S. N.
Lin, H. M.
Liu, Y.
Vranceanu, F.
Camidge, R.
Issue Date
2022
Metadata
Show full item recordCitation
Tiseo M, Popat S, Kim HR, Ahn M-J, Yang JC, Han J-Y, et al. 29P Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK+ non-small cell lung cancer (NSCLC): ALTA-1L final results. Vol. 33, Annals of Oncology. Elsevier BV; 2022. p. S44–5.Journal
Annals of OncologyDOI
10.1016/j.annonc.2022.02.038Additional Links
https://dx.doi.org/10.1016/j.annonc.2022.02.038Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.annonc.2022.02.038